Rossari Biotech Ltd management interview: Rossari Biotech Q2: Record ₹698 Crore Revenue, Exports Hit New High | Sunil Chari | Business News
ET Now, 2026-10-21. Video: https://www.youtube.com/watch?v=5nOfBDPVO_k
- Financial performance: Rossari reported record sales of ₹698 crore and EBITDA of ₹87 crore, with record exports of ₹221 crore. Net debt fell from ₹281 crore to ₹220 crore, and working-capital days declined from 96 to 87.
- Profit outlook: Management said higher finance costs should ease as debt falls; depreciation reflects investment for future growth. The company grew 20% in the first half versus the equivalent period last year, and expects new assets to add momentum in coming quarters.
- Growth guidance: The first half and second quarter were 20% higher in sales and EBITDA versus comparable periods last year. Management said growth could reach 20% if that pace continues, but geopolitical uncertainty makes the outlook difficult to quantify.
- Export expansion: Exports to the Americas and Europe were good, while the company is building business in the Middle East and Asia, including Japan, and has a formulation unit and stocking point in Thailand. Middle East exports increased in the last quarter and remained steady despite disruption.
- Saudi and margins: Rossari has taken land in Saudi Arabia and is finalizing feedstock and plans; management said the expansion could help double turnover in 4 to 5 years. It gave a margin level of around 12% and said it aims for above 15% EBITDA in the next 2 years.